Diagnostik og behandling af maturity onset diabetes of the young type 3
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Diagnostik og behandling af maturity onset diabetes of the young type 3. / Rose, Kathrine; Christensen, Alexander Sidelmann; Storgaard, Heidi; Hædersdal, Sofie; Hansen, Torben; Knop, Filip Krag; Vilsbøll, Tina.
In: Ugeskrift for Laeger, Vol. 180, V06170502, 2018.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Diagnostik og behandling af maturity onset diabetes of the young type 3
AU - Rose, Kathrine
AU - Christensen, Alexander Sidelmann
AU - Storgaard, Heidi
AU - Hædersdal, Sofie
AU - Hansen, Torben
AU - Knop, Filip Krag
AU - Vilsbøll, Tina
PY - 2018
Y1 - 2018
N2 - Maturity onset diabetes of the young type 3 (MODY3) is the most prevalent type of monogenetic diabetes. Treatment guidelines differ from both Type 1 diabetes and Type 2 diabetes. First-line treatment is a long-acting sulphonylurea, which lowers the plasma glucose level effectively, however with the risk of hypoglycaemia. When hypoglycaemia is a problem, short-acting sulphonylureas, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors may be used as alternatives. Metformin, glitazones and sodium glucose transporter 2-inhibitors have only limited applicability in MODY3. Further research needs to evaluate combinational therapy.
AB - Maturity onset diabetes of the young type 3 (MODY3) is the most prevalent type of monogenetic diabetes. Treatment guidelines differ from both Type 1 diabetes and Type 2 diabetes. First-line treatment is a long-acting sulphonylurea, which lowers the plasma glucose level effectively, however with the risk of hypoglycaemia. When hypoglycaemia is a problem, short-acting sulphonylureas, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors may be used as alternatives. Metformin, glitazones and sodium glucose transporter 2-inhibitors have only limited applicability in MODY3. Further research needs to evaluate combinational therapy.
KW - Diabetes Mellitus, Type 2/diagnosis
KW - Humans
KW - Hypoglycemic Agents/therapeutic use
KW - Insulin-Secreting Cells/metabolism
KW - Sulfonylurea Compounds/therapeutic use
M3 - Tidsskriftartikel
C2 - 29429476
VL - 180
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
M1 - V06170502
ER -
ID: 215864269